

List of Tables

S.N.	Name	Page No.
1.1	Top 10 countries/Territory for number of people with diabetes (20-79 years), 2013 and 2015	4
1.2	Available therapeutic agent for clinical diabetes management released since 1990	6
1.3	Available therapeutic agent and their side effect	7
1.4	DPP-4 inhibitors (approved and under development)	16
1.5	Pyrrolidilnes derivative DPP-4 inhibitors	38
1.6	Non-nitrile Pyrrolidilnes derivative DPP-4 inhibitors	42
1.7	Non Pyrrolidilnes derivative DPP-4 inhibitors	46
1.8	Non peptidomimetics DPP-4 inhibitors	51
1.9	DPP-8 and DPP-9 inhibitors	57
1.10	DPP II inhibitors	60
1.11	Main clinically relevant pharmacokinetics differences between the five dipeptidylpeptidase-4 inhibitors	65
3.1	Chemical structure and biological property of all compounds studied	89
3.2	Actual and predicted activity of developed models	92
3.3	Training set and test set distinction of developed models	93
3.4a	HQSAR analyses of model HQSAR	97
3.4b	Influence of various fragment sizes on key statistical parameters using the best fragment distinction (A, B, C and H) of model HQSAR A	97
3.5a	The HQSAR analyses of model HQSAR B	98
3.5b	Influence of various fragment sizes on key statistical parameters using the best fragment distinction (A, B, C and H) of model HQSAR B	99
3.6a	The HQSAR analyses of model HQSAR C	100
3.6b	Influence of various fragment sizes on key statistical parameters using the best fragment distinction (A, B, and H) of model HQSAR C	100
3.7	Actual and predicted activity of developed models	110
3.8	Summary of partial least-squares analysis results for the best common pharmacophore hypotheses (CPHs)	110
3.9	Summary of the results obtained from the COMFA and COMSIA analyses	111
3.10	Docking score and predicted activity of screened hits	121
4.1	Predicted activity and pharmacophore alignment score of designed molecules	124
4.2	Selectivity prediction of designed molecules by HQSAR models	124
4.3	Molecular properties of designed and synthesized compounds	147
4.4	Docking interaction results of designed and synthesized compounds	147
4.5	ADME properties of final compounds	149
5.1	Chemical structure and biological property of all compounds studied	156
5.2	Actual, predicted activity and pharmacophore fitness of developed models	165
5.3	Summary of partial least-squares analysis results for the best common pharmacophore hypotheses (CPHs)	166
5.4	Docking score and predicted activity of screened hits	168
5.5	Docking analysis of synthesized molecules	172
5.6	<i>In-silico</i> ADME analysis of synthesized molecules	173
5.7	<i>In-silico</i> toxicity studies data	174
S5.1	Scheme 5.1	175
5.8	Physical characterization of synthesized compounds	176
6.1	Groupings and treatment of animals for STZ model.	190
6.2	Histopathological observation	212